Clinical trial
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to…
NCT00025116 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00025116 |
|---|---|
| Title | ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | A Randomized Phase II Study Of ZD1839 (IRESSA) In Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Enrollment | 40 |
| Start date | Apr 24, 2001 |
| Primary completion | Jun 5, 2003 |
| Completion | Sep 22, 2008 |
| First posted | Sep 17, 2003 |
| Last update posted | Apr 6, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: